Louvain-La-Neuve, Belgium, and BELOIT, Wis., USA March 8, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |